Depression Screening Scores and Allergy and Gastrointestinal Medication Use in Adolescents.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2023-01-01 DOI:10.2174/1574886317666220826170140

Kari Harris, Pavithra Saikumar, Yojana Sunkoj, Trista Vancuren, Blessing Olufowote, Julian DeDedeaux

{"title":"Depression Screening Scores and Allergy and Gastrointestinal Medication Use in Adolescents.","authors":"Kari Harris, Pavithra Saikumar, Yojana Sunkoj, Trista Vancuren, Blessing Olufowote, Julian DeDedeaux","doi":"10.2174/1574886317666220826170140","DOIUrl":null,"url":null,"abstract":"Introduction: Between 2005 and 2014, the 12-month prevalence of major depressive episodes among adolescents aged 12 to 17 years increased from 8.5% to 11.3%. Adolescent-onset depression is related to increased risk for depression and suicidal attempts in adulthood. It is known that depression is an adverse effect among adults taking OAM; however, the effect of OAM on adolescents is unknown.Aim: The aim of this study was to describe the relationship between Patient Health Questionnaire 9- Modified (PHQ9-M) scores and OAM use among adolescents.Methods: This study included data abstracted from charts of adolescents aged 12 to 21 years who completed a Kansas Be Healthy wellness appointment at the KUSM-W Peds Clinic in 2017. Odds ratios were used to calculate the relationship between oral allergy medication and gastrointestinal medication use among adolescents and PHQ9-M scores.Results: Of the 425 adolescent charts analyzed, 22% (n=96) had positive PHQ9-M screens (a score of 10 or greater), and 13% (n=56) reported current use of allergy medication and/or GI medications. Adolescents taking oral allergy medication were 1.77 times more likely to have a positive PHQ9-M screen than those not taking oral allergy medication. Among adolescents on allergy medication, there was no difference in PHQ9- M scores based on the drug class (1st or 2<up>nd generation antihistamine or Montelukast).Conclusion: Healthcare providers must diligently explore OAM/GI use with adolescents during clinical encounters and discuss possible adverse effects of OAM on mood.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574886317666220826170140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Between 2005 and 2014, the 12-month prevalence of major depressive episodes among adolescents aged 12 to 17 years increased from 8.5% to 11.3%. Adolescent-onset depression is related to increased risk for depression and suicidal attempts in adulthood. It is known that depression is an adverse effect among adults taking OAM; however, the effect of OAM on adolescents is unknown.

Aim: The aim of this study was to describe the relationship between Patient Health Questionnaire 9- Modified (PHQ9-M) scores and OAM use among adolescents.

Methods: This study included data abstracted from charts of adolescents aged 12 to 21 years who completed a Kansas Be Healthy wellness appointment at the KUSM-W Peds Clinic in 2017. Odds ratios were used to calculate the relationship between oral allergy medication and gastrointestinal medication use among adolescents and PHQ9-M scores.

Results: Of the 425 adolescent charts analyzed, 22% (n=96) had positive PHQ9-M screens (a score of 10 or greater), and 13% (n=56) reported current use of allergy medication and/or GI medications. Adolescents taking oral allergy medication were 1.77 times more likely to have a positive PHQ9-M screen than those not taking oral allergy medication. Among adolescents on allergy medication, there was no difference in PHQ9- M scores based on the drug class (1^st or 2nd generation antihistamine or Montelukast).

Conclusion: Healthcare providers must diligently explore OAM/GI use with adolescents during clinical encounters and discuss possible adverse effects of OAM on mood.

查看原文本刊更多论文

青少年抑郁筛查评分与过敏和胃肠道药物使用。

2005年至2014年期间，12至17岁青少年中12个月重度抑郁发作的患病率从8.5%上升至11.3%。青春期发病的抑郁症与成年后抑郁和自杀企图的风险增加有关。众所周知，抑郁症是服用OAM的成年人的不良反应;然而，OAM对青少年的影响尚不清楚。目的:本研究的目的是描述青少年患者健康问卷9-修改(PHQ9-M)得分与OAM使用之间的关系。方法:本研究的数据摘自2017年在KUSM-W儿科诊所完成堪萨斯州Be Healthy健康预约的12至21岁青少年的图表。采用优势比计算青少年口服过敏药物和胃肠道药物使用与PHQ9-M评分之间的关系。结果:在分析的425个青少年图表中，22% (n=96)的PHQ9-M筛查呈阳性(得分为10分或更高)，13% (n=56)报告目前使用过敏药物和/或胃肠道药物。服用口服过敏药物的青少年PHQ9-M筛查阳性的可能性是不服用口服过敏药物的青少年的1.77倍。在接受过敏药物治疗的青少年中，基于药物类别(第一代或第二代抗组胺药或孟鲁司特)的PHQ9- M评分没有差异。结论:医疗保健提供者必须在临床接触中努力探索OAM/GI在青少年中的使用，并讨论OAM对情绪可能产生的不良影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.